228
Participants
Start Date
November 30, 2025
Primary Completion Date
October 31, 2028
Study Completion Date
February 28, 2029
TQB2825 Injection
TQB2825 is a Cluster of Differentiation 3 (CD3) × Cluster of Differentiation 20 (CD20) bispecific antibody.
Rituximab Injection
Rituximab combined with Chemotherapy (Rituximab, Cyclophosphamide, doxorubicin, Vincristine, Prednisone, Ifosfamide, Gemcitabine, cisplatin, Carboplatin, Etoposide, MESNA, Dexamethasone)
Beijing Cancer Hospital, Beijing
Shengjing Hospital Of China Medical University, Shenyang
The Second Hospital Of Dalian Medical University, Dalian
Affiliated Cancer Hospital of Harbin Medical University, Harbin
Ruijin Hospital, Shanghai Jiaotong University School of Medicine, Shanghai
Tongji Hospital of Tongji University, Shanghai
Jiangsu Province Hospital, Nanjing
Yantai Yuhuangding Hospital, Yantai
Linyi City People Hospital, Linyi
People's Hospital of Tianjin, Tianjin
Tianjin Cancer Hospital Airport Hospital, Tianjin
Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences, Tianjin
Jiangxi Cancer Hospital, Nanchang
The First Affiliated Hospital of Chongqing Medical University, Chongqing
People's Hospital of Hunan Province, Changsha
Hubei Cancer Hospital, Wuhan
Henan Cancer Hospital, Zhengzhou
The First Affiliated Hospital Of Zhengzhou University, Zhengzhou
Sun Yet-Sen University Cancer Certer, Guangzhou
The Affiliated Hospital of Guizhou Medical University, Guiyang
Hainan General Hospital, Haikou
The First People's Hospital Of Yunnan Province, Kunming
Yunan Cancer Hospital, Kunming
The First Affiliated Hospital of Xi'an Jiaotong University, Xi’an
Gansu Provincial Hospital, Lanzhou
General Hospital of Ningxia Medical University, Yinchuan
People's Hospital of Xinjiang Uygur Autonomous Region, Ürümqi
Shanxi Provincial Cancer Hospital, Taiyuan
Shanghai Chia Tai Tianqing Pharmaceutical Technology Development Co., Ltd.
INDUSTRY